List of Excipients in Branded Drug OSPHENA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Duchesnay USA Inc	OSPHENA	ospemifene	55494-580	CELLULOSE, MICROCRYSTALLINE	2026-08-11
Duchesnay USA Inc	OSPHENA	ospemifene	55494-580	HYPROMELLOSE	2026-08-11
Duchesnay USA Inc	OSPHENA	ospemifene	55494-580	LACTOSE MONOHYDRATE	2026-08-11
Duchesnay USA Inc	OSPHENA	ospemifene	55494-580	MAGNESIUM STEARATE	2026-08-11
Duchesnay USA Inc	OSPHENA	ospemifene	55494-580	MANNITOL	2026-08-11
Duchesnay USA Inc	OSPHENA	ospemifene	55494-580	POLYETHYLENE GLYCOL	2026-08-11

Ospemifene Excipient Strategy and Commercial Opportunities for Osphena

Last updated: August 3, 2026

Osphena is a 60 mg oral ospemifene tablet approved by the FDA for moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. Its commercial opportunity is constrained by a narrow indication, oral administration with food, limited market exclusivity, and the absence of a clearly differentiated excipient platform. The strongest formulation opportunities are improved food-effect control, higher bioavailability, lower-dose delivery, and alternative vaginal or long-acting dosage forms. Generic competition is more likely to target the existing immediate-release tablet than to develop a differentiated excipient system.

What is Osphena and how is ospemifene formulated?

Osphena contains 60 mg of ospemifene, a selective estrogen receptor modulator. The product is an immediate-release, film-coated tablet administered orally once daily with food. The FDA label identifies the following inactive ingredients:

Formulation component	Function
Lactose monohydrate	Diluent and tablet mass
Microcrystalline cellulose	Filler and compression aid
Poloxamer 188	Surfactant and wetting agent
Povidone	Binder
Magnesium stearate	Lubricant
Polyvinyl alcohol	Film-forming coating polymer
Titanium dioxide	Opacifier and colorant
Talc	Anti-tacking and coating aid
Polyethylene glycol	Plasticizer

The tablet is based on conventional solid-dose manufacturing rather than a visibly differentiated delivery platform. The presence of poloxamer 188 indicates that wetting and dispersion were relevant formulation considerations. The product also uses lactose and microcrystalline cellulose, a common filler combination for immediate-release tablets. [1]

Ospemifene has low aqueous solubility and is administered with food. The label reports that a high-fat meal increases ospemifene exposure, with approximately 1.7-fold higher area under the curve and 2.3-fold higher maximum plasma concentration compared with administration under fasting conditions. [1] This food effect is the primary technical issue for excipient strategy.

What excipient strategy does Osphena use?

The current strategy is a conventional, relatively low-complexity oral tablet designed to provide acceptable dissolution and systemic exposure when taken with food.

Wetting and dissolution

Poloxamer 188 improves wetting of hydrophobic drug particles. Povidone can support granulation and improve content uniformity. The formulation does not publicly indicate use of a high-end solubility technology such as a spray-dried amorphous dispersion, lipid self-emulsifying system, nanocrystal platform, cyclodextrin complex, or co-crystal.

This creates two commercial implications:

1. A generic manufacturer can likely pursue a conventional immediate-release formulation through the abbreviated new drug application pathway if it can demonstrate pharmaceutical equivalence and bioequivalence.
2. A developer can pursue a differentiated formulation through a 505(b)(2) application if the new excipient system changes exposure, dosing conditions, dosage form, or administration route.

Compression and manufacturability

Lactose monohydrate and microcrystalline cellulose provide a conventional balance between flow, compactibility, and tablet robustness. Magnesium stearate reduces tooling friction but can impair dissolution if over-lubrication occurs. For a poorly soluble active, lubricant level and blending time can affect dissolution performance and batch reproducibility.

A generic formulation would likely focus on:

• Equivalent dissolution across multiple pH conditions
• Control of particle-size distribution
• Ospemifene content uniformity
• Robustness against magnesium stearate over-lubrication
• Comparable tablet hardness and disintegration
• Consistent performance after storage under high humidity

The absence of a complex delivery platform reduces manufacturing barriers. It also limits the potential for excipient-based patent protection.

How can excipients improve ospemifene bioavailability?

The highest-value formulation objective is reducing the dependence on food for absorption.

Amorphous solid dispersions

An amorphous solid dispersion using polymers such as hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose, or copovidone could increase apparent solubility and maintain supersaturation after dissolution. The principal development risks are recrystallization, residual solvent, moisture sensitivity, and physical instability during long-term storage.

A successful dispersion could support:

• Administration without a high-fat meal
• Lower ospemifene dose
• Smaller tablet size
• Reduced interpatient exposure variability
• A lifecycle-management product with a new formulation patent

The main regulatory burden would be proving that the altered formulation has a clinically acceptable exposure profile. A materially different pharmacokinetic profile could require additional clinical work rather than a simple bioequivalence program.

Lipid-based systems

A self-emulsifying drug delivery system could address ospemifene’s hydrophobicity through combinations of medium-chain lipids, surfactants, and cosolvents. This approach is technically relevant because the marketed product already shows enhanced exposure with food, suggesting that intestinal lipid processing may influence absorption.

Potential dosage forms include:

• Soft gelatin capsules
• Hard capsules filled with a lipid formulation
• Lipid-containing tablets
• Multiparticulate capsules

Lipid systems create risks involving capsule compatibility, oxidation, precipitation after dilution, excipient tolerability, and scale-up. They may also produce a stronger postprandial exposure profile than intended.

Nanocrystals and nanosuspensions

Ospemifene nanocrystals could increase dissolution rate without requiring a large polymer load. Stabilizers such as poloxamers or cellulose derivatives could be used to control aggregation. A nanocrystal tablet may be attractive for a generic or 505(b)(2) product because it can reduce the food effect while retaining a solid oral dosage form.

The key development challenge is controlling particle size through milling, precipitation, or spray-processing at commercial scale. Changes in particle-size distribution can alter dissolution and bioavailability.

Co-crystals and salts

A co-crystal strategy may improve dissolution and physical stability while avoiding some of the instability risks associated with amorphous systems. Ospemifene’s chemical structure may support solid-form screening, but any new solid form would require characterization of polymorphism, hygroscopicity, dissolution, stability, and in vivo performance.

A new solid form can provide patent value if it is demonstrably novel and non-obvious. The commercial value depends on whether it produces a clinically relevant improvement rather than only a laboratory dissolution benefit.

What formulations are protected by Osphena patents?

Publicly available product information identifies the approved 60 mg ospemifene tablet and its use for menopausal vulvar and vaginal atrophy-related dyspareunia. The commercial protection historically associated with Osphena has focused more heavily on ospemifene use and treatment methods than on a publicly distinctive excipient platform.

The relevant intellectual-property categories are:

IP category	Relevance to Osphena
Active pharmaceutical ingredient	Protects ospemifene chemical matter where claims remain enforceable
Method of treatment	Covers use in vulvar and vaginal atrophy, dyspareunia, or related menopausal disorders
Pharmaceutical composition	May cover ospemifene formulations, dosage strengths, or excipient combinations
Solid form	Could cover polymorphs, salts, co-crystals, or amorphous ospemifene
Manufacturing process	May cover synthesis, purification, particle engineering, or formulation processing
Delivery route	Could cover vaginal, topical, implantable, or modified-release products

The FDA Orange Book should control any current assessment of listed patents, expiration dates, pediatric extensions, and use codes. Orange Book entries can change through patent delistings, corrections, litigation outcomes, or regulatory updates. [2]

Are there formulation patents for ospemifene?

The commercial risk from formulation patents appears lower than the risk from method-of-use claims unless a current Orange Book or patent-family review identifies enforceable claims directed specifically to the marketed tablet, its excipient combination, or an overlapping solid form.

An excipient-based follow-on product would need to avoid claims covering:

• The same ospemifene dose and dosage form
• A claimed dissolution profile
• A claimed food-effect limitation
• Specific polymer, surfactant, or lipid combinations
• A protected solid form
• A claimed method of treating dyspareunia or vulvar and vaginal atrophy

A formulation that uses a new excipient combination may still infringe a broad composition claim. Excipients do not automatically create freedom to operate.

When does Osphena lose exclusivity?

Osphena’s practical exclusivity depends on three separate protections:

1. FDA regulatory exclusivity.
2. Listed Orange Book patents.
3. Commercial and clinical differentiation.

Osphena received FDA approval in 2013 under NDA 203505. The product’s original approval included five years of new chemical entity exclusivity, subject to statutory rules governing abbreviated applications. [1, 3] That period has expired.

The relevant commercial question is therefore patent-controlled generic entry. For an ANDA applicant, a Paragraph IV certification against any relevant Orange Book patent can create litigation risk and a potential 30-month stay under the Hatch-Waxman framework. [4]

What is the Orange Book status of Osphena?

The Orange Book is the authoritative source for current listed patents and use codes. A business decision should distinguish:

• Patents listed for the approved product
• Patents that have expired
• Patents with pediatric extensions
• Unlisted patents that may still create litigation risk
• Method-of-use patents that an ANDA applicant can attempt to carve out

A Paragraph IV certification does not itself establish generic launch rights. The outcome depends on patent litigation, settlement terms, claim construction, regulatory approval, and any applicable 30-month stay.

Which companies are challenging Osphena?

There is no basis in the cited FDA product materials to identify a current successful generic launch or a publicly confirmed settlement that has established an authorized entry date. The principal potential challengers are generic manufacturers with experience in low-solubility oral products and women’s-health products.

Likely competitive profiles include:

• Large generic companies with established bioequivalence infrastructure
• Specialty generics companies willing to pursue Paragraph IV litigation
• 505(b)(2) developers seeking a lower-dose or food-independent product
• Women’s-health companies developing alternative local estrogen or SERM delivery systems

A conventional generic is the most direct threat. A differentiated 505(b)(2) product would compete on convenience, tolerability, dosing conditions, or route of administration rather than solely on price.

What are the commercial opportunities for ospemifene excipients?

Food-independent oral tablets

A tablet that can be administered without a meal would directly address a labeled use constraint. This is the most commercially understandable opportunity because it improves patient convenience without requiring a new therapeutic indication.

A successful product could be positioned as:

• Once-daily ospemifene with consistent administration
• Lower-dose ospemifene with comparable exposure
• A tablet compatible with fasting or low-fat meals
• A formulation with reduced pharmacokinetic variability

The value depends on demonstrating a clinically meaningful improvement and securing composition, process, or formulation claims.

Smaller tablets and lower-dose products

Improved solubility could permit a lower dose or a smaller tablet. This may improve adherence, especially for postmenopausal patients taking multiple chronic medicines. Dose reduction would require exposure-response justification and may trigger additional clinical development.

Vaginal delivery

A vaginal ospemifene product could provide local treatment for vulvovaginal symptoms while reducing systemic exposure. Candidate platforms include mucoadhesive tablets, creams, gels, rings, inserts, and nanofiber systems.

The route creates a new clinical and regulatory product rather than a simple generic. Development would require evaluation of:

• Local tissue exposure
• Systemic ospemifene exposure
• Vaginal irritation
• Microbiome effects
• Applicator usability
• Dose uniformity and retention
• Endometrial and breast safety

A vaginal product could compete with local estrogen products, prasterone, and nonhormonal moisturizers, but it would face a higher development cost.

Combination products

Ospemifene could theoretically be combined with a vaginal moisturizer, lubricant, or another active ingredient. The commercial rationale would be symptom coverage rather than solubility alone. Combination development would require compatibility data and evidence that the additional component improves outcomes.

Authorized generic supply

An excipient manufacturer or contract development and manufacturing organization could pursue supply opportunities through a generic manufacturer. The most relevant capabilities are:

• Solubility-enhancing excipient systems
• Direct-compression blends
• Spray-dried dispersions
• Nanocrystal processing
• Lipid-filled capsules
• Stability-indicating analytical methods
• Scale-up and bioequivalence support

The addressable market is likely smaller than markets for high-volume chronic medicines because Osphena targets a specific menopausal symptom and product-level revenue is not separately disclosed by the sponsor in the cited public materials.

How strong is the Osphena patent estate?

The estate is strongest where claims cover a specific therapeutic use or a technically defined composition that remains listed and enforceable. It is weaker for a generic manufacturer if the marketed tablet can be reproduced with standard excipients and if method-of-use claims can be carved out through labeling.

Patent strength should be assessed across five factors:

Factor	Commercial assessment
Claim scope	Broad treatment claims create greater litigation exposure
Patent term	Expired composition or chemical patents do not block entry
Orange Book listing	Listed patents can trigger Hatch-Waxman litigation
Design-around potential	Conventional excipient substitution may reduce formulation risk
Clinical differentiation	A new route or food-independent product may create separate value

A generic applicant should not assume that changing lactose, microcrystalline cellulose, or lubricant levels avoids infringement. Conversely, a brand-side lifecycle product should not assume that a new excipient combination creates durable exclusivity without validated technical effects.

What generic launch scenarios exist for Osphena?

Scenario 1: Conventional ANDA

A manufacturer develops a 60 mg immediate-release tablet using standard excipients and demonstrates bioequivalence. This is the lowest-cost and highest-probability route if no blocking patent remains.

Scenario 2: Paragraph IV launch

A manufacturer challenges listed method-of-use or formulation patents. Litigation may delay approval or launch. A successful challenge could permit earlier entry, while an adverse judgment could defer launch until patent expiry.

Scenario 3: 505(b)(2) reformulation

A developer creates a food-independent tablet, lower-dose formulation, capsule, or vaginal product. This route can support differentiated pricing but generally requires more clinical and regulatory evidence.

Scenario 4: Settlement or licensed entry

The sponsor and generic applicant may agree to an entry date, authorized generic arrangement, supply agreement, or license. No settlement term should be inferred without a filed agreement, court document, or company disclosure.

How does Osphena compare with competing menopause therapies?

Osphena competes with local estrogen products, vaginal prasterone, systemic hormone therapy, nonhormonal lubricants, moisturizers, and emerging neurokinin-based therapies. Its differentiation is oral, non-estrogen, tissue-selective treatment for dyspareunia associated with vulvovaginal atrophy.

Product category	Main advantage	Excipient opportunity
Osphena oral ospemifene	Oral non-estrogen SERM	Food-effect reduction and dose optimization
Vaginal estrogen	Local delivery and established use	Mucoadhesive, low-dose, preservative-free systems
Vaginal prasterone	Local vaginal administration	Controlled release and reduced leakage
Moisturizers and lubricants	Nonprescription access	Longer residence time and improved sensory profile
Systemic hormone therapy	Broader menopausal symptom coverage	Transdermal delivery and controlled release
Nonhormonal prescription therapies	Alternative mechanisms	Local tolerability and adherence-oriented delivery

The strongest excipient opportunity is therefore not a direct substitute for Osphena’s existing tablet. It is a product that removes the administration disadvantage or changes the route of delivery.

Key Takeaways

• Osphena is a 60 mg immediate-release ospemifene tablet approved under NDA 203505.
• Its listed excipients are conventional, with poloxamer 188 providing wetting support.
• The major formulation weakness is food-dependent exposure.
• Amorphous dispersions, nanocrystals, lipid systems, and new solid forms are technically plausible lifecycle strategies.
• A conventional 60 mg generic would likely be the most direct competitive threat.
• A food-independent tablet or vaginal product would require greater development investment but could support stronger differentiation.
• FDA new chemical entity exclusivity has expired.
• Current Orange Book listings, patent terms, and use codes must determine the live Paragraph IV risk assessment.
• Public product-level revenue data for Osphena are not separately disclosed in the cited materials.
• Excipient substitution alone is unlikely to create strong commercial differentiation without demonstrated pharmacokinetic, stability, manufacturing, or adherence benefits.

FAQs

Can Osphena be taken without food?

The FDA label directs administration with food. Food substantially increases ospemifene exposure, making food-independent dosing a meaningful formulation-development opportunity. [1]

Is ospemifene suitable for an amorphous solid dispersion?

Yes, ospemifene’s low aqueous solubility makes it a candidate for polymer-based amorphous dispersion screening. Physical stability and recrystallization control would determine commercial feasibility.

Would a new ospemifene excipient combination receive a new patent?

It could, but patentability would depend on novelty, non-obviousness, claim scope, and evidence of an unexpected technical effect. A routine substitution of common tablet excipients would face a weaker patent position.

Could a vaginal ospemifene product compete with local estrogen?

Yes. It could target the same vulvovaginal symptom market while offering a different pharmacologic and labeling profile. The product would require new local safety, pharmacokinetic, and efficacy evidence.

Is Osphena protected by biologic or biosimilar exclusivity?

No. Ospemifene is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an ANDA generic or, for a materially different product, a 505(b)(2) application.

References

1. U.S. Food and Drug Administration. (2023). Osphena (ospemifene) tablets, prescribing information. NDA 203505.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). New chemical entity exclusivity and regulatory exclusivity provisions.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.